Childress Capital Advisors’s AstraZeneca AZN Stock Holding History

Childress Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$269K	Sell	1,418 -79	-5%	-$14.9K	0.04%	297
2026 Q1	$295K	Sell	1,497 -44	-3%	-$8.48K	0.05%	262
2025 Q4	$283K	Buy	1,541 +81	+6%	+$14.2K	0.05%	293
2025 Q3	$224K	Buy	+1,460	New	+$221K	0.04%	286
2021 Q1	–	Sell	-678	Closed	-$68K	–	234
2020 Q4	$68K	Buy	+678	New	+$71.8K	0.04%	188

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BTCPP

Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

Childress Capital Advisors's AZN Position: Q2 2026 in Review

Childress Capital Advisors reduced its AstraZeneca (AZN) stake by 5.3% in Q2 2026, selling an estimated $14.9K and leaving 1,418 shares worth $269K. The position accounts for 0.04% of the portfolio, ranked #297.

Childress Capital Advisors first reported a position in AZN in Q4 2020 and has held it in 5 quarters since. The position peaked at $295K in Q1 2026. 488 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Childress Capital Advisors held 1,418 shares of AstraZeneca worth $269K as of Q2 2026.
Childress Capital Advisors sold 79 AstraZeneca shares in Q2 2026, an estimated $14.9K.
AstraZeneca made up 0.04% of Childress Capital Advisors's portfolio in Q2 2026, its #297 holding.
Childress Capital Advisors first reported a position in AstraZeneca in Q4 2020 and has held it in 5 quarters since.
Childress Capital Advisors's AstraZeneca position peaked at $295K in Q1 2026.
488 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Childress Capital Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.